The phase I clinical trial employed a double-blind, placebo-controlled, single ascending dose approach with the aim to assess the safety, tolerability, pharmacokinetic and pharmacodynamic effects of ALN-APP in patients with early-onset AD;12 the ALN-HTT02 trial has a similar design. Here, APP is linked to Alzheimer disease.